Cryo-Cell International (CCEL) vs NewGenIvf Group (NIVF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cryo-Cell International is the larger company by market cap ($33.5 million vs $80,770), about 414.3 times the size. On valuation, NewGenIvf Group trades at a lower forward P/E (0.0x vs 207.5x for Cryo-Cell International). NewGenIvf Group converts more of its revenue into profit, with a net margin of 209.0% versus -7.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCEL | NIVF |
|---|---|---|
| Share price | $4.15 | $0.0269 |
| Market cap | $33.46M | $80.77K |
| 1-day change | 0.00% | -23.14% |
| YTD return | +20.64% | — |
| 1-year return | +1.47% | — |
| 5-year return | -66.34% | — |
| Forward P/E | 207.50 | 0.00 |
| EPS (TTM) | $-0.24 | $-34,064.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $31.57M | $4.73M |
| Revenue growth (YoY) | -1.31% | -13.01% |
| Net income (latest FY) | $-2.43M | $9.88M |
| Gross margin | 76.63% | 20.22% |
| Operating margin | 1.53% | -226.95% |
| Net margin | -7.70% | 209.02% |
| 52-week high | $5.45 | $7,257.60 |
| 52-week low | $2.72 | $0.0229 |
| Distance from 52-week high | -23.85% | -100.00% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +472316.36% |
| Average volume | 13.02K | 6.57M |
| Shares outstanding | 8.06M | 2.99M |
| Employees | 72 | 87 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cryo-Cell International is about 414.3 times larger than NewGenIvf Group by market value ($33.46M vs $80.77K).
- NewGenIvf Group is more profitable, keeping 209.0 cents of every revenue dollar as net income versus -7.7 cents for Cryo-Cell International.
- Cryo-Cell International grew revenue faster in its latest fiscal year (-1.31% vs -13.01%).
About Cryo-Cell International
CCEL stock →Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.
Health Care · Misc Health and Biotechnology Services · 72 employees
About NewGenIvf Group
NIVF stock →NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing.
Health Care · Misc Health and Biotechnology Services · 87 employees
CCEL vs NIVF FAQ
Which is bigger, Cryo-Cell International or NewGenIvf Group?
Cryo-Cell International (CCEL) is larger, with a market capitalization of $33.46M compared with $80.77K for NewGenIvf Group (NIVF).
Are Cryo-Cell International and NewGenIvf Group in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.